endocrinology general-medicine
Diabetes Sick Day Risk Assessment
Identifies diabetic patients at risk of DKA or HHS during illness. Guides sick day rule application and hospital admission.
Used in: Diabetes & DKA
Score interpretation
Low risk — sick day rules at home
→ Continue insulin; increase monitoring Q1-2h; fluids; contact GP if worsening
Moderate risk — contact diabetes team
→ Contact diabetes team or out-of-hours; increase insulin if hyperglycaemic; IV access if vomiting
High risk — hospital assessment
→ Emergency department; venous blood gas; DKA/HHS protocol; IV fluids; fixed rate insulin infusion if DKA
Interpretation bands for the Sick Day Rules. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Sodium Chloride 3% (Hypertonic Saline) · Hypertonic Electrolyte Solution — ICP/Hyponatraemia Management
- Botulinum Toxin Type A (ENT) · Neuromuscular Blocking Agent (Botulinum Toxin)
- Tuberculin purified protein derivative · Mycobacterial antigen for delayed-type hypersensitivity testing
- Ethosuximide · Antiepileptic — T-type Calcium Channel Blocker
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.